Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Brooks Laboratories Ltd. Share Price
Day's Range
Day's Range
Low
₹66.00
High
₹67.75
Price Summary
| Previous Close | ₹67.10 |
|---|---|
| Day's Range | ₹66.00 - ₹67.75 |
| Open | ₹67.75 |
| 52 Week Range | ₹36.30 - ₹164.02 |
| Volume | 9,109 |
| Market Cap | ₹0.00 |
| Previous Close | ₹67.50 |
|---|---|
| Day's Range | ₹66.65 - ₹70.00 |
| Open | ₹66.65 |
| 52 Week Range | ₹36.90 - ₹165.95 |
| Volume | 633 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 6.11 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 8.15 |
| TTM EPS (₹) | 8.35 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 1.63 |
| PAT Margin (%) | -12.07 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -10.03 |
| Trade Value ( ₹ in Lacs) | 0.43 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 8.15 |
| TTM EPS (₹) | 8.35 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 1.63 |
| PAT Margin (%) | -12.07 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -10.03 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 825.57 | 233.17 |
| Expenses | N/A | N/A |
| PBT | -97.92 | 15.47 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -99.67 | 13.72 |
About Brooks Laboratories Ltd.
| Founded | 2002 |
|---|---|
| NSE Symbol | BROOKS |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,69,381.90 | 1,959.95 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,94,374.77 | 7,332.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,90,307.55 | 5,037.00 | 3,468.00 - 3,468.00 |
| Apollo Hospitals Enterprise Ltd. | 1,28,113.57 | 8,920.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,446.86 | 1,432.15 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,14,378.78 | 1,142.00 | 835.50 - 835.50 |
| Lupin Ltd. | 1,13,316.52 | 2,508.80 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,07,245.00 | 1,101.05 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,05,978.90 | 2,581.00 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 1,02,105.89 | 1,210.35 | 1,148.40 - 1,148.40 |
No Records Found
Latest News
Brooks Laboratories informs about partial sale of equity shares
Brooks Laboratories has informed that the Company at its board meeting held today, 19th June 2026 has approved sale of 51,220 equity shares held by the Company in Brooks Steriscience to Steriscience Specialities.
The above information is a part of company’s filings submitted to BSE.
Granules India informs about outcome of board meeting
GlaxoSmithKline Pharmaceuticals informs about board meeting
Pursuant to Regulations 29 & 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of our Company will be held on Monday, 3rd August 2026, to consider, approve and take on record the Un-audited financial results for the first quarter ended 30th June 2026.
The above information is a part of company’s filings submitted to BSE.
AstraZeneca Pharma India informs about resignation of CFO
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III thereto, AstraZeneca Pharma India has informed that, Bhavana Agrawal, Executive Director and Chief Financial Officer (‘CFO’) has communicated her resignation from the position of CFO (Key Managerial Personnel) of the Company with effect from the close of business hours on August 31, 2026, pursuant to her appointment to a regional role within the AstraZeneca Group. A copy of the resignation letter is enclosed as Annexure – A. Further, the details as required under the SEBI Master Circular SEBI/HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure – B.
The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals informs about press release
Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS® (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. With this approval, RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Brooks Laboratories Ltd. is ₹67.10 as of 2026-07-21.
The market capitalisation of Brooks Laboratories Ltd. is ₹200.31 as of 2026-07-20.
The 1-year return of Brooks Laboratories Ltd. is -88.75% as of 2026-07-21.
The P/E ratio of Brooks Laboratories Ltd. is 0.00 as of 2026-07-21.
The 52-week high and low of Brooks Laboratories Ltd. are ₹164.02 and ₹36.30, respectively, as of 2026-07-21.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
